Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06566443
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-09
Brief Title:
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention Female or male patients aged 18 years or older with early stage lung cancer who have been scheduled for curative surgery will be eligible for participation in the study The study will only enroll patients with stage I lung cancers less than 4 cm given the recent approval of neoadjuvant chemotherapy and nivolumab for stage IB tumors 4 cm Approximately 15 patients will be enrolled in the study They will take the study drug honokiol for 2 weeks prior to the surgery The primary endpoint will be the Maximum Tolerated Dose MTD of honokiol
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None